Physician profile
Fernando Miranda
NPI 1033144134
$1,305.77
in general payments reported to CMS, 2019-2025
24 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $279 · 2021: $438 · 2022: $69.48 · 2023: $90.75 · 2024: $161 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $362.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $350.34 | 2019-2021 | |
| Intuitive Surgical, INC. | $137.67 | 2020 | |
| Janssen Pharmaceuticals, INC | $114.29 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $76.67 | 2021 | |
| Sk Life Science, INC. | $68.98 | 2020-2024 | |
| Neurelis, INC. | $59.38 | 2021-2022 | |
| Tanabe Pharma America, INC. | $44.67 | 2024 | |
| Biogen, INC. | $44.08 | 2021-2022 | |
| Emd Serono, INC. | $37.46 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $37.06 | 2025 | Austedo Xr |
| Stryker Corporation | $32.85 | 2025 | Molli |
| Allergan, INC. | $30.59 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.15 | 2022 | |
| Acorda Therapeutics, INC | $27.63 | 2023 | Inbrija, Ampyra |
| Jazz Pharmaceuticals INC. | $26.15 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $24.93 | 2024 | Vyvgart Hytrulo |
| Merz Pharmaceuticals, LLC | $24.66 | 2024 | Xeomin |
| Insightec,INC | $23.52 | 2025 | Exablate |
| Biomarin Pharmaceutical INC. | $22.21 | 2024 | Brineura |
| Kyowa Kirin, INC. | $20.50 | 2023 | Nourianz |
| Abbvie INC. | $19.91 | 2023 | |
| Zimmer Biomet Holdings, INC. | $18.53 | 2020 | |
| Novo Nordisk INC | $18.39 | 2019 | |
| Averitas Pharma INC. | $17.15 | 2025 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Miranda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.